Clinical Trials Logo

X-Linked Retinitis Pigmentosa clinical trials

View clinical trials related to X-Linked Retinitis Pigmentosa.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04926129 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Natural History of the Progression of X-Linked Retinitis Pigmentosa

XOLARIS
Start date: September 13, 2017
Phase:
Study type: Observational

The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).

NCT ID: NCT03314207 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Start date: December 1, 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

NCT ID: NCT03252847 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Start date: July 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase 1 part of the study is a dose escalation of subretinal administration of AAV2/5 vector to assess the safety of this vector in participants with XLRP caused by mutations in RPGR. The Phase 2 part of the study is a cohort expansion of subretinal administration of AAV2/5 vector to assess the safety and efficacy of this vector in participants with XLRP caused by mutations in RPGR.

NCT ID: NCT03116113 Completed - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

XIRIUS
Start date: March 8, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).